HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California legislation

This article was originally published in The Rose Sheet

Executive Summary

Phthalates Free Cosmetics Act (AB 908), which would ban the use of di-butyl phthalate and di-(2-ethylhexyl) phthalate in cosmetics and personal care products in California, will be addressed by the Assembly Committee on Health May 3 (1"The Rose Sheet" April 4, 2005, p. 3). Authored by Assembly Member Judy Chu (D-49th), bill is similar to previous legislation introduced by Chu seeking to regulate cosmetic ingredients. Additionally, California Senate Health Committee postpones review of the California Safe Cosmetics Act of 2005 (SB 484), which was scheduled for an April 13 hearing. SB 484, introduced March 30 by Sen. Carol Migden (D-3rd), seeks to regulate the use of chemicals known to cause cancer or reproductive toxicity in cosmetics sold in the state...

You may also be interested in...



California Dreaming? Dems Re-Introduce Legislation To Regulate Cosmetics

Manufacturers of cosmetics subject to FDA regulation and sold in California would be required to report to the Department of Health Services any ingredient containing a chemical known to the state as causing cancer or reproductive toxicity under legislation pending in the state senate

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel